Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
Arvinas, Inc. reports that its license agreement with Rigel Pharmaceuticals and Pfizer for VEPPANU (vepdegestrant) is now effective after early Hart-Scott-Rodino antitrust clearance. Rigel has paid an aggregate $70.0 million upfront to Arvinas and Pfizer.
The partners are eligible for an additional $15.0 million upon completion of certain development and manufacturing transition work, and up to $320.0 million in future development, regulatory and commercial milestone payments, plus tiered mid-teens to mid-20s royalties on worldwide VEPPANU sales. All payments are to be split evenly between Arvinas and Pfizer, replacing unearned future amounts under their 2021 collaboration.
Arvinas, Inc. filed a current report outlining a portfolio re‑prioritization and updated plans for its ARV-806 program, along with an investor presentation for use at the Jefferies Global Healthcare Conference and other meetings.
After a strategic review, the company plans to complete the ongoing Phase 1 monotherapy dose escalation trial of ARV-806 in patients with solid tumors harboring KRAS G12D mutations and share clinical data in 2026. For any further development, such as dose expansion or combination trials, Arvinas intends to seek an out-licensing partner rather than advance ARV-806 alone. The company also reiterates that its cash, cash equivalents and marketable securities as of March 31, 2026 are expected to fund planned operating and capital spending into the second half of 2028.
ARVINAS, INC. President and CEO Randy Teel reported an automatic sale of 2,209 shares of common stock at $9.0365 per share. According to the footnote, the shares were sold by the company to cover tax withholding obligations tied to the vesting of RSUs granted on May 21, 2024, and the transaction was not a discretionary trade. After this tax-related sale, Teel directly holds 285,009 shares of Arvinas common stock.
Arvinas, Inc. notice reports proposed and completed transactions in the company’s common stock. The filing shows the settlement of vested restricted stock units for 2,197 shares on 05/21/2026 and two sales by Randy Teel: 4,786 shares on 02/23/2026 and 9,657 shares on 05/11/2026.
The filing lists gross proceeds of $58,197.76 and $95,965.47 tied to the two reported sales. The transactions are reported on a Form 144 filing and reflect individual dispositions and an RSU settlement; timing and method details are limited to the dates shown.
Arvinas, Inc.'s Chief Financial Officer Andrew Saik reported an automatic sale of 11,139 shares of common stock at $9.9374 per share. The shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units granted on May 9, 2025, and the transaction was not a discretionary trade. After this sale, Saik directly holds 193,128 shares of Arvinas common stock.
ARVINAS, INC. executive David K. Loomis, VP and Chief Accounting Officer, had 1,919 shares of common stock sold on May 11, 2026 at $9.9374 per share. According to the footnote, this automatic sale by the company covered tax withholding on vested RSUs and was not a discretionary trade. After this transaction, Loomis directly holds 40,193 shares of Arvinas common stock.
Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic share sale tied to tax withholding. On May 11, 2026, she sold 9,657 shares of common stock at $9.9374 per share. According to the footnote, this sale was made by the company to cover tax obligations from the vesting and settlement of RSUs granted on May 9, 2025 and "does not represent a discretionary trade." After the transaction, she directly owned 182,966 shares of Arvinas common stock.
Arvinas, Inc.’s Chief Medical Officer, Noah Berkowitz, reported a sale of 11,108 shares of common stock at an average price of $9.9374 per share on May 11, 2026. According to the filing, the sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of half of his RSUs granted on May 9, 2025, and is not a discretionary trade. Following this tax-related sale, Berkowitz directly holds 191,395 shares of Arvinas common stock.
ARVINAS, INC. reported that President and CEO Randy Teel had 9,657 shares of Common Stock sold on May 11, 2026 at an average price of $9.9374 per share.
According to the disclosure, this sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of restricted stock units granted on May 9, 2025, and is not a discretionary trade. Following the transaction, Teel directly holds 287,218 shares of Arvinas common stock.
Arvinas, Inc. reported first quarter 2026 results and highlighted a major strategic milestone: FDA approval of VEPPANU (vepdegestrant), the first-ever approved PROTAC protein degrader, for ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after at least one line of endocrine therapy. VEPPANU was also added as a Category 2A treatment in the NCCN Breast Cancer Guidelines and is being outlicensed globally to Rigel Pharmaceuticals, with closing subject to customary approvals.
For the quarter ended March 31, 2026, revenue was $15.6 million compared with $188.8 million a year earlier, mainly reflecting lower Pfizer collaboration revenue. Arvinas posted a net loss of $57.6 million versus net income of $82.9 million in the prior-year quarter. GAAP R&D expenses fell to $60.3 million and GAAP G&A to $19.1 million, with non-GAAP R&D and G&A at $54.3 million and $13.0 million, respectively. Cash, cash equivalents, and marketable securities totaled $614.9 million as of March 31, 2026, which the company believes will fund operations into the second half of 2028, while it advances a broad PROTAC pipeline including ARV-102, ARV-806, ARV-393, ARV-027, and ARV-6723.